Project Grant R21CA299559
Award Date 4/1/26
Completion Date 3/31/28
Dollars Obligated $458K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded $197,518 to The Children's Hospital of Philadelphia Research Institute under the Cancer Treatment Research program (CFDA 93.395) on September 8, 2025, with a completion date of August 31, 2030. This Project Grant supports the development of rare tumor clinical research capabilities and services to address the significant gap in clinical trial availability and patient care coordination for rare cancers. The awardee will expand...
- Federal Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded Penn State Milton S. Hershey Medical Center a $690,013 Project Grant on August 11, 2025, to conduct fundamental research on extracellular vesicles (EVs) in neuroblastoma treatment and drug resistance. The five-year project, concluding July 31, 2030, will deliver research findings and scientific knowledge aimed at developing novel therapeutic strategies targeting tumor-derived EVs...
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $767,328 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025 through July 31, 2030. The award funds research to investigate targeting splicing vulnerabilities in neuroblastoma, a malignancy responsible for 15% of childhood cancer-related deaths. The research will evaluate the efficacy and mechanisms of indisulam, a molecular glue...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $608,558 project grant under the Cancer Biology Research program (CFDA 93.396) to the Research Institute at Nationwide Children's Hospital, effective April 2, 2026 through March 31, 2031. This award supports fundamental research aimed at understanding the genetic and metabolic characteristics of high-risk neuroblastoma to develop novel precision and immunotherapy approaches. The research leverages genetically...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $768,713 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2030. This award supports fundamental research to advance understanding of epigenetic mechanisms controlling neuroblastoma cell state plasticity and treatment resistance. The project specifically investigates the role of histone...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded September 11, 2025, with completion targeted for August 31, 2030. The award supports fundamental research to identify and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs) as a therapeutic target for acute myeloid leukemia (AML) patients. The research...
- Federal Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $456,414 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2025, through April 30, 2030. This award supports the clinical development and evaluation of B7-H3 Chimeric Antigen Receptor (CAR) T cell therapy for children and young adults with Diffuse Intrinsic Pontine Glioma (DIPG), a fatal...
- Federal Project Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $470,759 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025, through August 31, 2027. The award supports the development of PA-Regulator Controlled, JMJD6 Reprogrammed GPC3-CAR T Cells for patients with hepatocellular carcinoma. The research addresses a critical...